ClinicalTrials.gg
CompletedNCT03747458Updated Sep 18, 2026

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

A Phase 3 interventional study of OPN-375 in Bilateral Nasal Polyposis, sponsored by Optinose US Inc.. Completed at 31 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 72 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

Read the detailed description

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

02

Conditions studied

  • Bilateral Nasal Polyposis
03

In context

Lead sponsor

Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).
  2. Female subjects, if sexually active, must,

    1. be practicing an effective method of (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be abstinent.
  3. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline).
  4. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening).
  5. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over a 7 day period during the single-blind run-in period. (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)
  6. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2015 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study (GINA 2015). Subjects receiving inhaled fluticasone alone or in combination may not participate in the PK sub-study.
  7. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). [Note: intranasal antibiotics and saline are permissible]
  8. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.
  9. Subjects (with assistance from parent or legal guardian if needed) must demonstrate the ability to complete the daily diary during the run-in period to be eligible for randomization.
  10. Must demonstrate correct use of the demo EDS.
  11. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Has a history of cystic fibrosis
  3. Have used XHANCE (fluticasone propionate) nasal spray within the past 2 months
  4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation
  5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation
  6. Have known history of nasal septum erosion, ulceration or perforation, or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy
  7. Other significant nasal pathology or abnormal anatomy
  8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)
  9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
  10. Have had any surgery on the nasal septum
  11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)
  12. History of any surgical procedure that prevents the ability to accurately diagnose or grade polyps
  13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  14. Have significant oral structural abnormalities (e.g., a cleft palate)
  15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks.
  17. Have an allergy, , or to or steroids
  18. Have a hypersensitivity to any in the study drug
  19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma
  20. Have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1
  21. Have nasal or oral candidiasis
  22. Have taken a potent -inhibitor within 14 days before Visit 1 (Screening)
  23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation
  24. History or current diagnosis of any form of glaucoma or ocular hypertension (i.e., >21 mm Hg)
  25. History of intraocular pressure elevation on any form of steroid therapy
  26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment
  27. A recent (within 1 year of Visit 1 [Screening]) history of drug or alcohol abuse or dependence
  28. Positive urine drug screen at screening visit for stimulants, opioids, or cocaine
  29. Have participated in an drug clinical trial within 30 days of Visit 1 (Screening)
  30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    OPN-375 186 μg BID

    Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks

    Drug: OPN-375

  • Placebo comparator
    Placebo

    Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks

    Drug: OPN-375

Interventions

06

What researchers measure

Primary outcomes

  1. Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4

    Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.

    Time frame: 4 Weeks

  2. Mean change from baseline at Week 16 in total polyp grade

    Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

    Time frame: 16 Weeks

Secondary outcomes

  1. Change in bilateral polyp grade over time

    nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

    Time frame: 16 Weeks

  2. Percentage of subjects with a ≥1 point improvement in polyp grade

    nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

    Time frame: 16 Weeks

  3. Percentage of subject with a grade of 0 on at least one side of the nose

    nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

    Time frame: 16 Weeks

  4. Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)

    The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

    Time frame: 16 Weeks

  5. Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)

    The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

    Time frame: 16 Weeks

  6. Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)

    The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

    Time frame: 16 Weeks

  7. Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)

    Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)

    Time frame: 16 Weeks

  8. The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase

    The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

    Time frame: 16 Weeks

  9. Subjects will assess their global impression of change since starting the study drug using the PGIC scale

    Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse

    Time frame: 16 Weeks

  10. Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).

    Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).

    Time frame: 16 Weeks

  11. Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)

    The assessment criteria are as follows: * Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months. * Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks. * Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks. * Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score \> 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.

    Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Other outcomes

  1. Assessment of safety from physical examination-measuring weight

    Assessment of safety from physical examination-weight measured in kg or lb

    Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

  2. Assessment of safety from physical examination-measuring height

    Assessment of safety from physical examination-height measured in cm or in

    Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

  3. Assessment of safety by recording the severity of AEs

    Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

    Time frame: 16 Weeks

  4. Assessment of safety by nasal examination

    Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

    Time frame: 16 Weeks

  5. Assessment of safety by ocular examination-visual acuity

    Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...

    Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

  6. Assessment of safety by ocular examination-Intraocular Pressure

    Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is \>21mmHg

    Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

  7. Assessment of safety by ocular examination-Cataract Evaluation

    Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe

    Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

  8. Assessment of safety measuring vital signs (blood pressure)

    Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

    Time frame: 16 Weeks

  9. Assessment of safety measuring vital signs (pulse)

    measure pulse in beats per minute (bpm)

    Time frame: 16 Weeks

  10. Assessment for safety from the collection of information for concomitant medications usage

    Time frame: 16 Weeks

  11. Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)

    PK Laboratory to determine the concentrations of fluticasone propionate \[AUC(0-t) (pg\*hr/mL) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

    Time frame: 8 hours, 1 to 2 weeks before randomization

  12. Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL)

    PK Laboratory to determine the concentrations of fluticasone propionate \[AUC(0-∞) (pg\*hr/mL) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

    Time frame: 8 hours, 1 to 2 weeks before randomization

  13. Assessment of pharmacokinetics - AUCex (%)

    PK Laboratory to determine the concentrations of fluticasone propionate \[AUCex (%) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

    Time frame: 8 hours, 1 to 2 weeks before randomization

  14. Assessment of pharmacokinetics - Cmax (pg/mL)

    PK Laboratory to determine the concentrations of fluticasone propionate \[Cmax (pg/mL) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

    Time frame: 8 hours, 1 to 2 weeks before randomization

  15. Assessment of pharmacokinetics - tmax (h)

    PK Laboratory to determine the concentrations of fluticasone propionate \[tmax (h) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

    Time frame: 8 hours, 1 to 2 weeks before randomization

  16. Assessment of pharmacokinetics - t1/2 (h)

    PK Laboratory to determine the concentrations of fluticasone propionate \[t1/2 (h) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

    Time frame: 8 hours, 1 to 2 weeks before randomization

07

Study locations

31 sites
  • San Tan Allergy & Asthma
    Gilbert, Arizona 85234, United States
  • Kern Research
    Bakersfield, California 93301, United States
  • Central California Clinical Research
    Fresno, California 93720, United States
  • Sensa Health
    Los Angeles, California 90006, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Allergy and Asthma Consultants
    Redwood City, California 94063, United States
  • Sacramento ENT
    Roseville, California 95661, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Chicago ENT
    Chicago, Illinois 60657, United States
  • Kentuckiana ENT
    Louisville, Kentucky 40205, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Allergy Asthma & Immunology Research Institute
    Charlotte, North Carolina 28204, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Carolina ENT
    Orangeburg, South Carolina 29118, United States
  • STAAMP Research
    San Antonio, Texas 78229, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Eastern Virginia Medical School - Otolaryngology
    Norfolk, Virginia 23507, United States
  • Spokane ENT
    Spokane Valley, Washington 99216, United States
  • Instituto Medico Rio Cuarto
    Río Cuarto, Córdoba Province X5008AEV, Argentina
  • Instituto Medico de la Fundacion de Estudios Clinicos - Consultorios Integrados Rosario
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Centro de Investigaciones Clinicas - Instituto de la Salud Rosario
    Rosario, Santa Fe Province S200DBS, Argentina
  • Clinica Mayo, UMCB
    San Miguel de Tucumán, Tucumán Province T4000IHE, Argentina
  • Sanatorio Guemes
    Buenos Aires, C1180AAX, Argentina
  • Fundacion CIDEA
    Buenos Aires, C1411ABE, Argentina
  • InAER - Investigaciones en Alergia y Enfermedades Respiratorias
    Buenos Aires, C1425BEN, Argentina
  • Instituto de Asma Alergia y Enfermedades Respiratoria (IAAER)
    Corrientes, W3400AVV, Argentina
  • Centro Medico INSARES
    Mendoza, M5500CCG, Argentina
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Mar 2026, 87 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2018
First posted
Nov 20, 2018
StartActual
Dec 31, 2018
Primary completionActual
Mar 31, 2026
CompletionActual
Jun 11, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03747458
Lead sponsor
Optinose US Inc.
Collaborators
Paratek Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Dec 31, 2018
Primary completion
Mar 31, 2026
Completion
Jun 11, 2026
Last update
Sep 18, 2026

Study contacts

Amy Manley
study chair · Paratek Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion